RNAi-based therapeutics

History:

Ribopharma merged with Alnylam in 2003 and is now Alynylam Europe.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Europe

Research Focus:
RNAi Disease Therapeutics-Research Therapeutics-Development

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: